Replimune Group, Inc. announced Jason Rhodes, partner at Atlas Venture, has resigned from the company's Board of Directors. Mr. Rhodes joined the Replimune Board in 2015, concurrent with Atlas Venture leading Replimune's Series A financing. Mr. Rhodes has resigned to focus his efforts on his growing commitments at Atlas Venture, including the recent launch of its new fund, announced in March 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.65 USD | -4.72% | -15.33% | -32.50% |
05-16 | Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
04-08 | Replimune Group Provides Interim Results for Skin Cancer Therapy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.50% | 364M | |
+64.21% | 62.59B | |
-1.73% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.75% | 26.21B | |
-21.75% | 19.09B | |
+4.42% | 13.08B | |
+25.73% | 12.26B | |
+28.27% | 12.05B |
- Stock Market
- Equities
- REPL Stock
- News Replimune Group, Inc.
- Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors